Valvular & structural heart disease
Applying the TRILUMINATE Eligibility Criteria to Real-World Patients Receiving Tricuspid Valve Transcatheter Edge-to-Edge Repair
Authors' conclusion
The observed differences in survival and HFH outcomes suggest a limited generalizability of TRILUMINATE to real-world conditions
Study context
- Population
- Real-world patients who underwent transcatheter tricuspid edge-to-edge repair (T-TEER) at 5 European centres, 2016–2022
- Participants
- 962 patients
- Exposure
- TRILUMINATE-eligible vs TRILUMINATE-ineligible patients
- Outcome
- Symptomatic and survival outcome
Methodological detailsmulticentre (5 European centres)
- Multicentre (5 European centres)
Main finding
As reported in the abstract
Survival and HF hospitalisation · 1 year
Survival
HF hospitalisation
Observational data: associations, not effects.
Further findings
TR ≤2+ at discharge
TR reduction, NYHA class, quality of life, exercise capacity
- Comparable in both groups
Baseline characteristics
- Eligible had superior LV function and fewer comorbidities
Original publication
Applying the TRILUMINATE Eligibility Criteria to Real-World Patients Receiving Tricuspid Valve Transcatheter Edge-to-Edge Repair. JACC Cardiovasc Interv. Published 20 November 2023. doi:10.
Summarised from the published abstract; every number is checked against it